Last reviewed · How we verify
Metastasis from malignant tumor of colon
Approved treatments
- Carac · Spectrum Pharms
- Xeloda · Cheplapharm
Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells. - Eloxatin · Yakult Honsha
Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription. - Eylea · Texas Retina Associates
- Camptosar · Pfizer
Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks. - Carac · Extrovis
- Camptosar · Pfizer
Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing. - Vegf Trap · Regeneron
- Stivarga · Bayer
Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis. - Camptosar · Pfizer
Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death. - Xeloda · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Clinical guidelines
- FDA label — 2L
Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - FDA label — 3L+
STIVARGA is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. - FDA label — 3L+
STIVARGA is indicated for the treatment of adult patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. - FDA label — 2L
STIVARGA is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastasis from malignant tumor of colon patent landscape — cliff calendar, originator estates, attackable patents
- Metastasis from malignant tumor of colon treatment landscape brief
- Metastasis from malignant tumor of colon treatment updates RSS
Frequently asked questions about Metastasis from malignant tumor of colon
What drugs treat Metastasis from malignant tumor of colon?
Tracked treatments include Carac, Xeloda, Eloxatin, Eylea, Camptosar, Vegf Trap, Stivarga.
What is the treatment for Metastasis from malignant tumor of colon?
Standard treatment for Metastasis from malignant tumor of colon includes Carac, Xeloda, Eloxatin, Eylea, Camptosar. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Metastasis from malignant tumor of colon?
FDA label publishes guidelines for Metastasis from malignant tumor of colon. 4 guideline references tracked.
Related
- Treatment landscape: Metastasis from malignant tumor of colon patent cliff · Metastasis from malignant tumor of colon CI report
- Treatment: Carac · Spectrum Pharms
- Treatment: Xeloda · Cheplapharm
- Treatment: Eloxatin · Yakult Honsha
- Treatment: Eylea · Texas Retina Associates
- Treatment: Camptosar · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing